Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

NCT00675090 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: GSK239512
DRUG: Placebo

Sponsor

GlaxoSmithKline